<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ARegulatory_approval_for_acquisition</id>
	<title>Definition:Regulatory approval for acquisition - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ARegulatory_approval_for_acquisition"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Regulatory_approval_for_acquisition&amp;action=history"/>
	<updated>2026-05-02T16:23:34Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Regulatory_approval_for_acquisition&amp;diff=20731&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Regulatory_approval_for_acquisition&amp;diff=20731&amp;oldid=prev"/>
		<updated>2026-03-18T03:15:25Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;🔍 &amp;#039;&amp;#039;&amp;#039;Regulatory approval for acquisition&amp;#039;&amp;#039;&amp;#039; is the formal authorization that must be obtained from one or more insurance [[Definition:Regulatory authority | regulatory authorities]] before a change of control or significant ownership stake in a [[Definition:Regulated entity | regulated entity]] — such as an [[Definition:Insurance carrier | insurer]], [[Definition:Reinsurance company | reinsurer]], or [[Definition:Insurance holding company | insurance holding company]] — can be completed. Unlike acquisitions in many unregulated industries, purchasing a controlling interest in an insurance business is not simply a matter of agreeing on price and closing; regulators in virtually every major insurance market require advance notification and approval, reflecting the public-interest dimension of insurance and the need to protect [[Definition:Policyholder | policyholders]] from unsuitable owners.&lt;br /&gt;
&lt;br /&gt;
⚙️ The approval process typically involves the acquiring party submitting detailed information about its financial strength, source of funds, corporate structure, management qualifications, and strategic intentions for the target company. Regulators assess whether the proposed new owners meet fit-and-proper standards, whether the acquisition would compromise the target&amp;#039;s [[Definition:Solvency | solvency]] or [[Definition:Capital adequacy | capital position]], and whether it could create undue concentration or [[Definition:Systemic risk | systemic risk]]. Thresholds that trigger the requirement vary by jurisdiction: in the United States, the Insurance Holding Company System Regulatory Act generally requires approval for acquisitions of 10% or more of a domestic insurer&amp;#039;s voting securities, while EU member states under [[Definition:Solvency II | Solvency II]] apply qualifying holding thresholds and specific assessment criteria harmonized across the bloc. In China, the [[Definition:China Banking and Insurance Regulatory Commission (CBIRC) | CBIRC]] (now the National Financial Regulatory Administration) has imposed increasingly rigorous scrutiny on acquisitions of insurance companies, particularly regarding the source and nature of capital. Multi-jurisdictional deals — such as a global [[Definition:Private equity | private equity]] firm acquiring a reinsurer with subsidiaries in Bermuda, the UK, and Singapore — may require parallel approvals from each relevant supervisor, adding complexity and timeline risk.&lt;br /&gt;
&lt;br /&gt;
⏳ Securing regulatory approval is often the longest and most uncertain phase of an insurance acquisition, and its requirements shape deal structure from the outset. Bidders in competitive processes factor in the likelihood and timeline of approval when pricing and structuring offers; a buyer perceived as a poor regulatory fit may be at a disadvantage regardless of the financial terms offered. Conditions or [[Definition:Remedies package | remedies]] imposed by regulators — such as requiring the buyer to maintain minimum capital levels, retain key management, or divest certain business lines — can materially alter the economics of a transaction. In recent years, heightened regulatory scrutiny of [[Definition:Private equity | private equity]] acquisitions of insurers, particularly in the [[Definition:Life insurance | life]] and [[Definition:Annuity | annuity]] sectors, has underscored the evolving expectations that supervisors place on new owners regarding long-term stewardship, investment strategy, and policyholder outcomes.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Regulated entity]]&lt;br /&gt;
* [[Definition:Remedies package]]&lt;br /&gt;
* [[Definition:Change of control]]&lt;br /&gt;
* [[Definition:Solvency II]]&lt;br /&gt;
* [[Definition:Insurance holding company]]&lt;br /&gt;
* [[Definition:Fit-and-proper requirements]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>